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Highlights 
 A direct effect of imiquimod is demonstrated on hemangioma cells in vitro. 
 Imiquimod impairs motility and disorganize actin cytoskeleton on hemangioma cells. 
 Hemangioma but not normal endothelium undergo apoptosis upon imiquimod treatment. 
 
Abstract 
Infantile hemangiomas are the most common benign tumors of infancy, characterized by unregulated 
angiogenesis and endothelial cells with high mitotic rate. Although spontaneous regression occurs, sometimes 
treatment is required and alternatives to corticosteroids should be considered to reduce side effects. 
Imiquimod is an imidazoquinoline, approved for some skin pathologies other than hemangioma. It is proposed 
that the effectiveness of imiquimod comes from the activation of immune cells at tumor microenvironment. 
However, the possibility to selectively kill different cell types and to directly impede angiogenesis has been 
scarcely explored in vitro for endothelial cells. In this work we showed a dramatic cytotoxicity on hemangioma 
cell, with a significant lower IC50 value in hemangioma compared to normal endothelial cells and melanoma 
(employed as a non-endothelial tumour cell line). Nuclear morphometric and flow-cytometry assays revealed 
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imiquimod-induced apoptosis on hemangioma and melanoma cells but a small percentage of senescence on 
normal endothelial cells. At sub-lethal conditions, cell migration, a key step in angiogenesis turned out to be 
inhibited in a tumor-selective manner along with actin cytoskeleton disorganization on hemangioma cells. 
Altogether, these findings pointed out the selective cytotoxic effects of imiquimod on transformed endothelial 
cells, evidencing the potential for imiquimod to be a therapeutic alternative to reduce extensive superficial 
hemangioma lesions. 
 
Keywords: Imiquimod; Hemangioma; Endothelium; Cytotoxicity. 
 
1. Introduction. 
Infantile hemangiomas (IH) are benign tumours of the vascular endothelium constituted by endothelial cells 
with high mitotic rate and stromal components such as fibroblasts, mast cells and pericytes (1). IH are 
characterized by a rapid postnatal growth (2, 3) and in most cases, these lesions do not need treatment as 
they resolve spontaneously within the first years of life without major sequellae (4). When involution does not 
occur or specific location in vital structures compromise functional impairment, treatment include topical, 
intralesional and systemic corticosteroids, cryosurgery, interferon, vincristine, radiation or laser therapy (5-10). 
Propranolol is now considered first-line therapy for complicated and cosmetically challenging IH (11, 12), 
however side effects can be life threatening or produce recurrence (13,14). Since 2002 several American and 
European reports have suggested the efficacy and safety of the topical application of imiquimod (IQ) for IH 
treatment (15-18). IQ is a small molecule also known as S-26308 or R-837, included into an immune response 
modifier agents group (19, 20). Topical IQ has been reported to be effective in the treatment of lentigo maligna 
(21, 22), melanoma metastases (23), cutaneous anogenital warts (24), actinic keratosis (AK) (25, 26) and 
superficial basal cell carcinoma (BCC) (27-29). Even though it has not been approved for IH by US Food and 
Drug Administration (FDA) yet, some clinical trials were designed and safety has been proven for superficial 
IH (28, 29).  
IQ activates TLR7 and this activation is MyD88 dependent, leading to the induction of the transcription factor 
NF-kB which positively regulates the activity of both the innate and acquired immune responses (32, 33). By 
inducing IFN-α and other cytokines, IQ is able to enhance T-helper cells (Th1) response by indirectly 
stimulating the IFN-ɣ release through IFN-α former liberation from the innate immune cells (34, 35). Little is 
known about the direct activity of IQ and especially on hemangioma. Therefore, it is particularly intriguing 
whether IQ directly affects tumour cells triggering other mechanisms than immune stimulation. Even more 
interesting is the idea of IQ contributing to an antineoplastic effect by distinguishing between normal and tumor 
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cells. Herein, we studied the cytotoxic effects of IQ on hemangioma cells and compared differential effects on 
melanoma, a non-endothelial model of tumor cells, and normal endothelial cells, assessing viability and 
relevant morphological cell aspects such as actin cytoskeleton distribution and nuclear structure. 
 
2. Materials and Methods. 
2.1 Cells Culture Conditions and Reagents 
Three established murine cell lines were used in this study: H5V as hemangioma model (36), 1G11 as normal 
endothelium (37) and the melanoma cell line B16-F1 (ATCC® CRL-6323™). Cells were routinely maintained in 
Dulbecco’s modified Eagle’s medium (DMEM, Sigma-Aldrich, Saint Louis, USA) supplemented with 10% fetal 
bovine serum (FBS, Natocor, Córdoba, Argentina), 2 mM L-glutamine, 100 U/mL penicillin and 100 µg/mL 
streptomycin. 1G11 medium was supplemented with 2 mM sodium pyruvate and 1 % non-essential amino 
acid. Cells were incubated in 5% CO2 atmosphere at 37°C. Media was changed after reseeding 2-3 times a 
week. Cell detachment was performed employing trypsin-EDTA solution. Cultures were routinely tested to be 
mycoplasma-free. IQ (kindly provided by Cassará Laboratories) was prepared as 1 mg/mL stock solution of IQ 
in pyrogen-free distilled water (pH=2) by heating-homogenization cycles. Cell culture confluency was 
approximately 80% confluency at the time of treatment. Results obtained after treating cells with vehicle were 
strictly comparable to those obtained with cells untreated.    
 
2.2 Cell Viability Assay and IC50 Estimation 
All cell lines (3x104 cells/well) were plated onto 96 flat-bottom multiwell and incubated with increasing 
concentrations of IQ (0-100 µg/mL) in 5% FBS-supplemented DMEM for 24 hs.  Supernatants were discarded 
and cells fixed with 4% paraformaldehyde (PFA) for 15 minutes. After washing once with PBS, cells were 
stained using 0.1% crystal violet dye for 30 minutes. Stained cells were washed twice with distilled water and 
the dye was solubilized with water:methanol:acetic acid (85:10:5) solution. Optical density (OD) at 595 nm was 
measured using a FLUOstar OPTIMA Microplate Reader (BMG LABTECH GmbH, Ortenberg, Germany) to 
calculate viability percentage (%V) as: 
%𝐕𝐢𝐚𝐛𝐢𝐥𝐢𝐭𝐲 =  
𝐎𝐃 𝐭𝐫𝐞𝐚𝐭𝐞𝐝 𝐜𝐞𝐥𝐥𝐬
𝐎𝐃 𝐮𝐧𝐭𝐫𝐞𝐚𝐭𝐞𝐝 𝐜𝐞𝐥𝐥𝐬
 𝐱 𝟏𝟎𝟎 (Equation 1) 
Relative inhibitory concentration 50% (IC50) values for IQ were calculated with a 4-parameter logistic model 
using OriginPro 9.1 software (OriginLab Corporation) software (38). The four parameters shown in Figure 1 
were calculated with the Origin Pro 9.1 software as the best-fit values in the model by an iterative procedure. 
 
2.3 Cell Migration and Scratch Assay 
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Confluent monolayers were carefully wounded using a sterile 1000 µL tip, making three scratches horizontally 
and three vertically. After washing several times with fresh culture medium to remove the cell debris, cultures 
were incubated for 12 hs either with 5% FBS-supplemented DMEM as control or the same medium 
supplemented with increasing concentrations of IQ (1-10 µg/mL). After fixation with 4% PFA for 15 minutes, ≥ 
50 pictures were taken along the wounds avoiding wound intersections. The free-cell area (FCA) was 
quantified with DP2-BSW Olympus software and the percentage of migration (%M) was calculated as 
indicated in Equation 2 
%𝐌 = (
𝐅𝐂𝐀 𝐨𝐟 𝐭𝐫𝐞𝐚𝐭𝐞𝐝 𝐜𝐞𝐥𝐥𝐬
𝐅𝐂𝐀 𝐨𝐟 𝐮𝐧𝐭𝐫𝐞𝐚𝐭𝐞𝐝
 𝐜𝐞𝐥𝐥𝐬
)
−𝟏
 𝐱 𝟏𝟎𝟎 (Equation 2) 
 
2.4 Phalloidin-TRITC Staining for Stress Fibres 
Endothelial H5V, 1G11 and melanoma B16-F1 cells (1x104 cells/well) were seeded overnight onto 1% collagen 
I coated glass coverslips. Subsequently, cells were cultured for 12 hs in the absence or presence (1-10 µg/mL) 
of IQ. To allow staining, after fixation with 4% PFA for 15 minutes, cells were permeabilized with 0.2% Triton™ 
X-100 (Sigma-Aldrich, Saint Louis, USA) for 15 minutes, washed three times with a 0.05% Triton™ X-100/PBS 
solution and incubated for 1 hour with a solution containing 1 µg/mL phalloidin-TRITC and 1 µg/mL Höescht 
33458.  Cell images were taken using an Olympus BX40F-3 fluorescence microscope and analyzed using 
Image J Pro Plus 6.0 software (IPP6-Media Cybernetics, Bethesda, MD, USA). 
 
2.5 Flow Cytometry and Nuclear changes detection through Nuclear Morphometric Assay (NMA) 
Cells were treated for 24 hs with increasing concentrations of IQ (0-10 µg/mL). For each condition, adherent 
and detached cells were collected and resuspended in binding buffer (1x106 cells/mL) to detect apoptotic and 
necrotic cells following the FITC Annexin V Apoptosis detection kit instructions (BD Biosciences, CA, USA). 
The cells were acquired in a Flow cytometer (BD FACSAriaTM II, BD Biosciences, Becton, Dickinson and 
Company) and the results analyzed using the FlowJo vX.0.7 software (Tree Star, Inc). For NMA cells were 
fixed and stained with a 10 µg/mL Höescht 33458 in PBS for 1 hour. Images were taken using an Olympus 
BX40 fluorescence microscope with an original magnification of 400X. The analysis was performed with 
ImageJ Pro Plus 6.0 tool Nuclear Irregularity Index (NII) as described (39). It included as many random 
pictures as to compile 500 nuclei for each experimental condition.  
 
2.6 Statistical Analysis 
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Results were expressed as mean ± S.E.M of three independent experiments. Data were analyzed by one-way 
ANOVA followed by Tukey HSD post-test by using Origin Pro 9.1 software. Prior to ANOVA, data were tested 
for normality and homogeneity of variance using the Shapiro–Wilk and Levene’s tests, respectively by using 
Origin Pro 9.1 software as well.  Pairwise comparisons between IC50 were done using Student t-test. 
 
3. Results. 
3.1 IQ affects cell viability of transformed cells in a tumor-selective manner. 
We assessed whether IQ was capable to exert a selective cytotoxic effect in vitro in the absence of immune 
cells. For this purpose, H5V transformed endothelial cells as hemangioma model and normal microvascular 
1G11 cells were compared. B16F-1 melanoma cells were included as a model of a non-related skin tumor, 
which could also be responsive to IQ. When assayed in the presence of increasing concentrations of IQ, 
ranging 0-100 μg/mL, a steep drop in cell viability was consistently observed for both H5V and B16 cells in a 
concentration-dependent manner. Each IC50 was significantly different from the other (Table I). H5V 
hemangioma cells presented a relative IC50 four-folds lower than for 1G11, indicative that H5V exhibited a 
higher susceptibility (Figure 1B). After 24 hs treatment, H5V cytotoxicity reached 85-90% compared with 
untreated cells, a result also obtained for melanoma cells (Figure 1B).  Therefore, we were able to 
demonstrate not only the selective effect of IQ but also its direct in vitro effect on different endothelial cells. 
 
3.2 IQ induces apoptosis on hemangioma cells 
We further characterized cell death through flow cytometry to elucidate whether IQ triggered an apoptotic or 
necrotic cell death. After IQ treatment of H5V cells for 24 hours, a striking dose-dependent (0-10 µg/mL) 
increase was observed in the Annexin V-FITC/PI positive cell population (Figure 2 A-D), reaching a maximum 
of 60% of the cells for the highest concentration (Figure 2E). A similar behavior was observed for melanoma 
cells (data not shown). When 1G11 cells were cultured in the presence of IQ, a slight dose-dependent (0-10 
µg/mL) death was appreciated (Figure 2 F-I), reaching a maximum of 10%-15% of the cells which is within the 
basal cell death found in routine cultures (Figure 2J). Consequently, hemangioma but not normal endothelial 
cells would undergo an apoptotic death, supporting the idea of a selective cytotoxic effect on transformed cells 
for IQ.  
In order to gain further insight about nuclear morphology changes to complement the results obtained by flow 
cytometry, NMA was performed. Alterations in nuclear morphology are expected to occur during physiologic 
processes, like mitosis or throughout cell death such as nuclear constriction and fragmentation observed in 
AC
CE
PT
ED
 M
AN
US
CR
IPT
7 
 
apoptosis (39, 40). According to NMA assay we were able to distribute nuclei in four separate populations: 
normal (N), apoptotic (small regular, SR), senescent (large regular, LR) or irregular (I).  
In absence of IQ, both H5V and 1G11 showed 80-85 % N nuclei with round-shaped and well-defined regular 
surfaces (Figure 3 A, F, E and J). It is worth mentioning that shapes parameters and average area of nuclei 
from both lines are different. In fact, 1G11 nuclei are about 30% bigger than H5V in normal culture conditions 
and they have a similar NII (S1, supplementary material).  
When increasing IQ concentrations (5-10 µg/mL) hemangioma cells exhibited a significantly abundant 
population (65-75%) of shrunken and pyknotic regular (SR) nuclei, consistent with an apoptotic morphology 
(Figure 3 C, D and E). On the other hand, IQ-treated 1G11 completely lacked of SR nuclei population. 
However, there was a significant increase (20-25%) of LR nuclear morphology compared to untreated cells, 
evidence consistent with a senescent nuclear phenotype (Figure 3 H, I and J). These findings strongly support 
the idea of IQ triggering an apoptotic program on hemangioma cells but not in normal endothelial 1G11. 
Moreover, these results revealed a new population of senescent cells that were disregarded at the flow 
cytometry analysis and could be part of the double negative population in cytometric determinations. The 
presence of senescent cells under IQ treatment was exclusively confirmed in IQ-treated 1G11 cultures by 
detection of senescence-associated beta-galactosidase (SA-β-gal) (data not shown). 
 
3.3 Cell migration is inhibited on IQ-treated melanoma and hemangioma cells.  
Hemangiomas are highly vascularized tumors. A key step during angiogenesis is cell migration, process also 
significant for tumor cells to invade towards surrounding and distant tissue. Due to its relevance, we decided to 
investigate whether IQ is able to interfere in normal cell behavior under sub-lethal time conditions. To assess 
the possibility of IQ having an inhibitory role in cell migration, we performed scratch assays on both endothelial 
and melanoma cells. In the absence of IQ and 12 hs after wounding, there was a substantial influx of migrating 
cells into the FCA of the wound (Figure 4 A, D and G) and taken as the maximum migration. On the contrary, 
when IQ was added to the cultures (1-10 µg/mL), no wound closure was evident for H5V or B16F-1 cells after 
12 hs treatment (Figure 4 C, E and F), representing a 40% drop in migration for H5V cells and 60% for 
melanoma cells (Figure 4J). Nonetheless, IQ treatment had no significant effect on normal endothelial cell 
migration with respect to control cultures for all assessed concentrations of IQ (Figure 4 G, H, I and J). Of 
note, the absence of migration on IQ treated cells was not due to cell death or detachment from the plate 
(Figure 4). Consequently, the inhibitory effect of IQ on migration was more important on H5V and B16F-1 
cells. 
 
3.4 IQ selectively induces cell depolarization and stress fibres loss on hemangioma cells. 
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Cell polarization and actin stress fibers formation play a key role in the migratory phenotype orchestrated by 
the cytoskeleton (CSK). In order to explain whether IQ effects on cell migration were attributable to changes in 
actin CSK, we performed phalloidin-TRITC staining on IQ-treated cells (0-10 µg/mL) for 12 hours. Surprisingly, 
the presence of IQ specifically affected H5V hemangioma cells actin CSK but neither 1G11 CSK nor B16F-1 
melanoma cells CSK were altered (Figure 5 A). In the absence of IQ (first column, Figure 5 A), the vast 
majority of the cells were polarized and showed actin stress fibres at the longitudinal axis, extending a broad 
lamellipodium at the leading edge (green arrows) and a narrow trailing edge at the rear (white arrows). When 
cells were treated with IQ, H5V depolarized and became rounded along with increasing concentrations of the 
drug (Figure 5 A, first row). Quantification of cell with non-polarized morphology indicated a significant 
increase of cells with rounded shape and absence of actin stress fibres associated to IQ concentrations ≥ 5 
µg/mL (Figure 5B). On the contrary, B16F-1 and 1G11 cells exhibited no changes in its actin arrangements 
and displayed a migratory, fibroblast-like morphology similar to their control counterparts (Figure 5 A, second 
and third rows respectively). These results could explain migratory defects on hemangioma cell when treated 
with IQ and highlights the selective effect of the compound.   
 
4. Discussion. 
The use of IQ on hemangiomas is an off-label use and its potential benefit in the treatment of this vascular 
pathology has been only shown in some case reports that involved a reduced number of patients (15-18). This 
drug is known as a TLR7 agonist capable to stimulate Th1 response (19, 20). Here, we demonstrated that in 
the absence of such activated immune response, IQ was able to reduce cell viability in a tumor-selective 
fashion on hemangioma and melanoma cells. This cytotoxic effect of IQ is a relevant finding since scarce 
research works have shown such antitumor effect at lower concentrations than 50 μg/mL (42, 43).  
In consonance with the Nomenclature Committee on Cell Death (NCCD), in absence of clear biochemical 
biomarkers a cell must be consider dead if: (a) the cell is able to incorporate vital dyes such as propidium 
iodide (PI) in vitro, indicating permeability loss; (b) both the cell and its nucleus have become fragmented into 
discrete bodies (apoptotic bodies); (c) apoptotic bodies can be recognized through phosphatidylserine 
exposure (41). Our results showed an augmented PI-positive cells population upon IQ treatment, which could 
be indicative of late apoptosis/necrosis. However, NMA did not show the same proportion of swelling nuclei. 
Consequently, the PI-positive fraction of IQ-treated H5V was understood as a late apoptotic population. More 
interestingly, our data revealed that the treatment induced apoptosis preferentially on transformed endothelial 
cells but not on its normal counterpart where only a small fraction was senescent. This selective induction on 
transformed endothelial cells is an encouraging result, which may contribute to control non-involuted IH. These 
original findings for endothelial lineage should be confirmed by in vivo assays but are in agreement with 
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results obtained from biopsy of patients with BCC treated with topical IQ. Biopsy images of these patients 
showed complete remission of the tumor tissue while the surrounding normal tissue remained healthy (27, 28).  
Interestingly, under sublethal treatment conditions, we found that IQ was capable of inhibiting tumor cell 
migration of hemangioma and melanoma cells. According to our results, cell motility inhibition was related to 
actin cytoskeleton disorganization in hemangioma but not in melanoma cells. Thereby, IQ would inhibit 
migration affecting different components of motile cell cycle in different tumor cell types, an aspect that should 
be further investigated.  
Altogether, these data which were not previously described in vitro on hemangioma cells encourage us to 
perform in vivo studies and open an interesting possibility to consider the use of topical IQ to control superficial 
IH or to contribute to reduce the time of treatment of conventional therapies. 
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Legends to Figures 
 
Figure 1. IQ affected cell viability of transformed cells. (A) Structural formula of Imiquimod (1-(2-
Methylpropyl)-1H-imidazole [4, 5-c] quinoline-4-amine).  (B) Effect of increasing concentrations of IQ on cell 
types viability. Values are shown as Mean ± SEM, N= 3. All cell types showed a cell viability drop in a 
concentration-dependent manner (H5V p<0.0001; B16F-1 p<0.0001; 1G11 p<0.0001). Curves are fits to the 
logistic equation with A1 being the maximum percentage of viability; A2 the minimal percentage of viability and 
“p” the steepness of the dose–response curve. IC50 values are detailed. 
Figure 2. IQ-induced apoptosis on hemangioma cells. One of two representative flow cytometry plots of 
Annexin V-FITC/IP staining performed on H5V cells (A-E) and 1G11 cells (F-I). A concentration-dependent 
apoptosis appeared in hemangioma cells after IQ treatment but minor percentages were observed for normal 
endothelial cells (A, F = 0 µg/mL; B, G= 1 µg/mL; C, H= 5 µg/mL and D, I: 10 µg/mL).  (E and J) Bar graphics 
showing the percentage (%) of cells in each quadrant for each IQ concentration as mean ± SEM from two 
independent experiments. 
Figure 3. IQ induced apoptosis on hemangioma and senescence in normal endothelial cells.  
Representative images of stained nuclei with Höescht 33458 for hemangioma (H5V, A-E) and normal 
endothelium (1G11, F-I) cells. A significantly augmented population of SR nuclei for IQ-treated hemangioma 
cells (C-D) but a reduced population of LR for IQ-treated normal endothelial (H-I) cells with respect to 
untreated cells (E, J; *, p<0.01). A, F: 0 µg/mL; B, G: 1 µg/mL; C, H: 5 µg/mL and D, I: 10 µg/mL. Original 
magnification 400X. (E and J) Bar graphics showing the percentage (%) of nuclei in each population for each 
concentration of IQ as mean ± SEM from three independent experiments. N: normal nuclei.  
Figure 4. Inhibition of transformed cell migration upon IQ treatment. Phase contrast images after 12 h of 
IQ treatment. Original magnification 100X. H5V and B16F-1 migration was significantly reduced at 5 µg/mL IQ 
(*p<0.05) and (**p<0.0015), respectively. H5V: 0 µg/mL (A), 1 µg/mL (B) and 5 µg/mL (C). B16F-1: 0 µg/mL 
(D), 5 µg/mL (E) and 10 µg/mL (F). 1G11: 0 µg/mL (G), 5 µg/mL (H) and 10 µg/mL (I). H5V treatment with 10 
µg/mL was not recorded since cell death was evident at 12 hs for this concentration. Dotted lines mark the 
edges at the start of the experiment. (J) Migration percentage (%M, according to equation 2) versus IQ 
concentrations. Data plotted are mean ± SEM of 3 independent experiments.   
Figure 5. IQ selectively induces cell depolarization and stress fibres lost on hemangioma cells. 
Melanoma (B16F-1) and endothelial 1G11 cells displayed migratory, fibroblast-like, morphologies with a 
leading (A, green arrows) and trailing edge (A, white arrows). No changes in actin stress fibres organization or 
content is shown. Stress fibres were stained with phalloidin-TRITC (red) and nuclei with Höescht 33458 (blue). 
Original magnification 400X. (B) Cell count (%) for each IQ concentration (µg/mL) showing significant 
increasing number of hemangioma (H5V) cells (*p<0,005) with loss of migratory morphology. Bars represent 
the mean ± SEM of 3 independent experiments. CSK=cytoskeleton. 
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Cell line A1 A2 p R
2 IC50 
(µg/mL) 
IC50  
(µM) 
H5V 100.0 ± 0.0 12.0 ± 0.0 1.6 ± 0.3 0.9627 09.5 ± 1,4 39.5 ± 05.8 
B16F-1 100.0 ± 0.0 11.0 ± 0.0 1.4 ± 0.2 0.9935 20.0 ± 3.0  83.2 ± 12.5 
1G11 100.0 ± 0.0 35.0 ± 0.0 3.0 ± 0.6 0.9571 37.2 ± 2.9 155.0 ± 12.0 
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Table I. P-values of the pairwise comparison of IC50 values between the three cell lines assayed. 
 
IC50 contrasts p-value 
H5V vs. 1G11 p<0.01 
H5V vs. B16F-1 p<0.01 
B16F-1 vs. 1G11 p<0.01 
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